CN109937041A - 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 - Google Patents

一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 Download PDF

Info

Publication number
CN109937041A
CN109937041A CN201880004347.XA CN201880004347A CN109937041A CN 109937041 A CN109937041 A CN 109937041A CN 201880004347 A CN201880004347 A CN 201880004347A CN 109937041 A CN109937041 A CN 109937041A
Authority
CN
China
Prior art keywords
alkyl
inhibitor
heterocycle
alkoxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004347.XA
Other languages
English (en)
Other versions
CN109937041B (zh
Inventor
马珂
曹国庆
杨昌永
张连山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN109937041A publication Critical patent/CN109937041A/zh
Application granted granted Critical
Publication of CN109937041B publication Critical patent/CN109937041B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明涉及一种EZH2抑制剂与BTK抑制剂联合在制备治疗肿瘤的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201880004347.XA 2017-05-18 2018-05-17 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 Active CN109937041B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710350614 2017-05-18
CN2017103506146 2017-05-18
PCT/CN2018/087246 WO2018210296A1 (zh) 2017-05-18 2018-05-17 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途

Publications (2)

Publication Number Publication Date
CN109937041A true CN109937041A (zh) 2019-06-25
CN109937041B CN109937041B (zh) 2022-04-12

Family

ID=64273344

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004347.XA Active CN109937041B (zh) 2017-05-18 2018-05-17 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途

Country Status (13)

Country Link
US (1) US11065239B2 (zh)
EP (1) EP3626239A4 (zh)
JP (1) JP7125952B2 (zh)
KR (1) KR102635949B1 (zh)
CN (1) CN109937041B (zh)
AU (1) AU2018269262B2 (zh)
BR (1) BR112019023632A2 (zh)
CA (1) CA3058241A1 (zh)
MX (1) MX2019012938A (zh)
MY (1) MY201580A (zh)
RU (1) RU2762893C2 (zh)
TW (1) TWI810185B (zh)
WO (1) WO2018210296A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10626116B2 (en) * 2016-01-05 2020-04-21 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of BTK kinase inhibitor and preparation method thereof
EP3890782A2 (en) * 2018-12-03 2021-10-13 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Ezh2- fgfr inhibition in cancer
CN111499642A (zh) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法
CN110372562B (zh) 2019-07-09 2021-04-06 上海再启生物技术有限公司 一种btk激酶抑制剂关键中间体的晶型及其制备方法
WO2021063332A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067300A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
CN103987842A (zh) * 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
US20150065483A1 (en) * 2011-02-28 2015-03-05 Epizyme, Inc. Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
WO2015146159A1 (en) * 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
CN105263496A (zh) * 2013-04-08 2016-01-20 药品循环有限责任公司 依鲁替尼联合疗法
CN105263497A (zh) * 2013-04-08 2016-01-20 拜耳制药股份公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US20160303135A1 (en) * 2013-12-06 2016-10-20 Epizyme, Inc. Combination therapy for treating cancer
WO2016014859A1 (en) * 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
KR20180081587A (ko) * 2015-11-19 2018-07-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤조푸란 유도체, 이의 제조 방법 및 의학에서의 이의 용도

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065483A1 (en) * 2011-02-28 2015-03-05 Epizyme, Inc. Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
CN103987842A (zh) * 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
WO2013067300A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
CN105263496A (zh) * 2013-04-08 2016-01-20 药品循环有限责任公司 依鲁替尼联合疗法
CN105263497A (zh) * 2013-04-08 2016-01-20 拜耳制药股份公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途
WO2015146159A1 (en) * 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UITDEHAAG, JOOST C. M等: "Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors", 《MOLECULAR CANCER THERAPEUTICS》 *

Also Published As

Publication number Publication date
AU2018269262B2 (en) 2021-12-02
MY201580A (en) 2024-03-02
US20210030736A1 (en) 2021-02-04
TWI810185B (zh) 2023-08-01
CN109937041B (zh) 2022-04-12
KR102635949B1 (ko) 2024-02-14
JP7125952B2 (ja) 2022-08-25
TW201900171A (zh) 2019-01-01
RU2019138222A (ru) 2021-06-18
EP3626239A1 (en) 2020-03-25
JP2020519588A (ja) 2020-07-02
AU2018269262A1 (en) 2019-10-31
US11065239B2 (en) 2021-07-20
BR112019023632A2 (pt) 2020-08-18
CA3058241A1 (en) 2018-11-22
EP3626239A4 (en) 2021-03-10
RU2019138222A3 (zh) 2021-07-30
MX2019012938A (es) 2019-12-16
RU2762893C2 (ru) 2021-12-23
KR20200007851A (ko) 2020-01-22
WO2018210296A1 (zh) 2018-11-22

Similar Documents

Publication Publication Date Title
CN109937041A (zh) 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
CN109562106B (zh) Cxcr4抑制剂及其用途
CN107922431B (zh) Hpk1抑制剂及其使用方法
KR102449712B1 (ko) 아미노티아졸 화합물 및 이의 용도
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
CN101222850B (zh) 治疗对药物有抗性的癌症的方法
CN101723936A (zh) 激酶抑制剂及其在药学中的用途
CN105541836A (zh) 激酶抑制剂的前药形式及其在治疗中的用途
CN109982701B (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
WO2016155545A1 (zh) 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用
JP7164203B2 (ja) ピロロ芳香族複素環化合物及びその製造方法並びに医薬用途
TW201836606A (zh) 一種ｍｏｒ激動劑與ｋｏｒ激動劑聯合在製備緩解和／或治療疼痛的藥物中的用途
JP2017503815A (ja) がんまたは炎症性疾患を処置するための置換されたピロロピリジンおよびピロロピラジン
CN109563088B (zh) MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
TW202019409A (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用
CA3176325A1 (en) Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
JP2020523348A (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
CN111303133A (zh) 降解ezh2蛋白的小分子化合物
CN115381832A (zh) 癌症的治疗
JP2020147594A (ja) 新規なジヒドロピラノピリミジノン誘導体およびその用途｛Ｎｏｖｅｌ ｄｉｈｙｄｒｏｐｙｒａｎｏｐｙｒｉｍｉｄｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ、ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝
CA3231467A1 (en) Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors
JP2015533834A (ja) Ｒａｃ−ＧＴＰアーゼ媒介疾患を処置するための化合物
WO2020074010A1 (zh) 治疗化疗难治性癌症的新联合用药方案
CN114105977A (zh) 雌激素受体调节剂化合物及其用途
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009120

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant